Quantitative and sensitive methods for measuring PGD synthase are essential. In this study, we developed a highly sensitive and specific assay for PGD svnthase by using two monoclonal antibodies against the enzyme and detecting terbium chelates labels with time-resolved fluorescence spectroscopy. This assay can be used for measuring PGD synthase in various human tissues and fluids.
Prostaglandins, metabolites of arachidonic acid, have a wide variety of biological functions [1] . Prostaglandin D2 (PGD2) is a potent inhibitor of platelet aggregation in vitro and is involved in smooth muscle contraction and relaxation [2] . PGD, has been implicated in a variety of functions of the central nervous system (CNS), including synaptic transmission [3] ,hypothalamic control of temperature [4] , recovery from seizures [5, 6] , and release of lutropin [7] . PGD, is also implicated in sedation and sleep induction [8, 9] . Hayaishi et al. [10] [11] [12] have provided strong evidence that PGD2 is involved in sleep induction in rats and monkeys. Prostaglandin D synthase (prostaglandin-H, D-isomerase, EC 5.3.99.2; PGD synthase) catalyzes the conversion of PGH2 to PGDJ [13] . This enzyme is responsible for the biosynthesis of PGD, in the brain and is localized in the CNS [14] .Postnatally, the cellular location of the enzyme changes, and the enzyme is now thought to play important roles in both maturation and maintenance of the CNS.
Nagata et a!. [15] , 'White et al. [16] ,Urade et al. [17] , and Igarashi et al. [18] have cloned the human and rat PGD synthase genes and have shown that PGD synthase belongs to a superfamily of secretory proteins called lipocalins. Lipocalins share a common feature for binding and transport of small hydrophobic molecules [19] . Among the 26 members of this superfamily, PGD synthase shows the greatest homology with 24p3 oncogene product protein, suggesting a close evolutionary relationship between these two proteins [18] . \ATe have recently found that PGD synthase is expressed in various tissues and is present in numerous fluids, including normal breast tissue [20] , breast tumors [21] , breast cyst fluid [21, 22] , milk of lactating women [21, 23] , and amniotic fluid [21, 24j . At present, PGD synthase can be measured by semiquantitative 'ATestern blot analysis [21] .
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and sensitive methods for measuring PGD synthase are essential. In this study, we developed a highly sensitive and specific assay for PGD svnthase by using two monoclonal antibodies against the enzyme and detecting terbium chelates labels with time-resolved fluorescence spectroscopy. This assay can be used for measuring PGD synthase in various human tissues and fluids. Fraction number
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Assay. Pipet 50 ML of standards or samples (appropriately diluted in the SA-ALP diluent, see below) into coated microtiter wells and add 50 ML of the biotinylated antibody solution diluted 1000-fold in assay buffer. Incubate with mechanical shaking for 2 h at room temperature and then wash six times. To each well add 100 ML of SA-ALP conjugate diluted 20 000-fold in the Obtained with capillary glass tubes after mechanical pressure of breast; '-5 L collected per patient.
Obtained from lactating women -1 week postpregnancy. (Fig. 2) .
In dilution experiments (Fig. 3) , near-linear dilution curves were obtained with all samples tested, when the samples were by adding PGD synthase to various sample matrices ( Table 2) . In many cases, we supplemented diluted matrices because the initial concentration in these fluids was >50 MgJL (our upper calibrator concentration). The recovery was acceptable in all cases, except for one notable exception of one amniotic fluid with no measurable P(il) synthase. The recovery in this sample was 9-14%, whereas the recovery for the same sample after 500-fold dilution was 109-111%. Subseqtint studies, as described below, showed that this fluid contained endogenous proteolytic activity that completely degraded the PGD synthase. When testing another, less sensitive version of this assay, we also found that undiluted amniotic fluids could not be measured accurately but required at least 20-fold dilution; this suggests that PGD synthase interacts and binds with some components of amniotic fluid (probably lipids).
We further analyzed various fluids and extracts to determine their PGD synthase concentration ( Table  3 ). The highest concentration was found in CSF, followed by (in order) urine, amniotic fluid, seminal plasma, and breast discharge fluid. Small but significant amounts of PGD synthase were also detected in serum and other fluids. The data are not sufficient for detailed clinical conclusions; however, we can make the following observations (r = Pearson correlation coeffIcient): Among the few amniotic fluids tested, one was unique in having no detectable PGD synthase concentration. We postulated that this fluid may contain proteases that degrade PGD synthase. To study this possibility, we examined the stability of PGD synthase in this fluid (after addition of the enzyme) and in other fluids (Table 4) . PGD synthase was stable for at least 24 h at 37 #{176}C in CSF, urine,serum, and BSA solution, whereas both This is the amniotic fluid with proteolytic activity and low recovery(see Table 2 ). "Nanograms of PGDsynthase per milligram oftotal protein.
aAs in Table 5 . native and recombinant PGD synthases were completely degraded in the amniotic fluid under question. PGD synthase remained stable in serum and in BSA solution for as long as 10 days at 37 #{176}C but declined by -30% and 60% in CSF and urine, respectively. We prepared cytosolic extracts of various fetal tissues obtained from an aborted fetus with trisomy 21 and of placentas obtained from aborted fetuses at various gestational ages. The extracts were analyzed for PGD synthase and for total protein.
The results are shown in Table 5 for fetal tissues and Table 6 for placentas. Among all fetal tissues tested, PGD synthase content was greatest in the brain and --10-fold lower in the fetal heart. The other tissues contained comparatively less amounts of the enzyme. In placental tissue, PGD activity was low until gestational week 9, increased at gestational weeks 11-28, and declined slowly until term. A similar pattern for PGD synthase concentration was seen in the amniotic fluid (already described).
We obtained fetal blood and the corresponding amniotic fluid from two fetuses and compared the concentrations in the two fluids. In fetus A, the PGD synthase concentration in amniotic fluid was 2000 MgIL; the corresponding serum concentration was 600 Mg/L (ratio 3.3). In fetus B, the amniotic fluid concentration was 1900 Mg/L and the serum concentration was 750 ,.LgIL (ratio 2.5). Measurement of another five fetal sera that became available showed PGD synthase concentrations of 300, 500, 450, 400, and 350 p.g/L. These values are similar to those for PGD synthase in sera from men and women (Table 3) . protein, given the lack of monoclonal antibodies and pure protein stocks. After the PGD synthase gene was cloned [16- 18/, it became apparent that PGD synthase and 13-trace are the same proteins. The recombinant protein was produced, and monoclonal antibodies were developed. The present method is based on monoclonal antibodies raised against recombinant PGD synthase and use of a highly sensitive detection technique, enzymatically amplified time-resolved fluorometry [25] . The glycosylation differences between recombinant PGD synthase and native PGD synthase in biological fluids have not as yet been examined.
The optimized assay has a detection limit of 0.05 Mg/L and a dynamic range extending to 50 MgIL. The assay is highly specific for PGD synthase: It does not recognize any other proteins in various animal sera, and it does recognize a single protein of molecular mass 27 kDa in all fluids and extracts tested. As shown, assay validation through precision, recovery, and dilution experiments gave satisfactory results. breast discharge fluid, breast milk, and breast tumor extracts. We presented evidence that, at least in some amniotic fluids, the PGD synthase is rapidly proteolyzed. In fetal tissues, PGD synthase is present at highest concentrations in the brain, followed by the heart; other tissues contain considerably less. Placental extracts show the highest concentrations during gestational weeks 11-28, which paralleled the peak values seen in amniotic fluid. These data highly suggest that the source of PGD synthase in amniotic fluid is the placenta.
In fetal blood, the PGD synthase concentrations are similar to those found in
adults.
The measurement of PGD synthase has not as yet found clinical applications, given that the already described assays are semiquantitative and relatively insensitive. The new assay developed in this study is 100-to 1000-fold more sensitive and has excellent specificity and analytical performance. We are now in the process of evaluating whether the measurement of PGD synthase has value in diseases of the brain or other organs or in malignant diseases, including breast cancer. Additionally, we are examining its measurement in seminal plasma for evaluation of infertility and its measurement in amniotic fluid and maternal serum for evaluation of fetal status during pregnancy. We anticipate that this assay will help further knowledge of PGD synthase and its role in human pathobiology.
